Turning Point Therapeutics, Inc.
TPTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $30,829 | $25,000 | $0 | $0 |
| % Growth | 23.3% | – | – | – |
| Cost of Goods Sold | $0 | $25,000 | $0 | $0 |
| Gross Profit | $30,829 | $0 | $0 | $0 |
| % Margin | 100% | 0% | – | – |
| R&D Expenses | $192,979 | $113,411 | $57,943 | $21,062 |
| G&A Expenses | $75,850 | $73,425 | $19,781 | $4,578 |
| SG&A Expenses | $75,850 | $73,425 | $19,781 | $4,578 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $268,829 | $186,836 | $77,724 | $25,640 |
| Operating Income | -$236,551 | -$161,836 | -$77,724 | -$25,640 |
| % Margin | -767.3% | -647.3% | – | – |
| Other Income/Exp. Net | $1,449 | $4,544 | $5,593 | $856 |
| Pre-Tax Income | -$236,551 | -$157,292 | -$72,131 | -$24,784 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$236,551 | -$157,292 | -$72,131 | -$24,785 |
| % Margin | -767.3% | -629.2% | – | – |
| EPS | -5.79 | -3.85 | -2.99 | -1.66 |
| % Growth | -50.4% | -28.8% | -80.1% | – |
| EPS Diluted | -5.79 | -3.85 | -2.99 | -1.66 |
| Weighted Avg Shares Out | 40,844 | 40,844 | 24,125 | 14,938 |
| Weighted Avg Shares Out Dil | 40,844 | 40,844 | 24,125 | 14,938 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $856 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,967 | $2,393 | $1,579 | $138 |
| EBITDA | -$232,584 | -$154,899 | -$70,552 | -$24,646 |
| % Margin | -754.4% | -619.6% | – | – |